Comparisons of Immunoassay and Mass Spectrometry Measurements of Serum Estradiol Levels and Their Influence on Clinical Association Studies in Men


**Context:** Immunoassay-based techniques, routinely used to measure serum estradiol (E2), are known to have reduced specificity, especially at lower concentrations, when compared with the gold standard technique of mass spectrometry (MS). Different measurement techniques may be responsible for the conflicting results of associations between serum E2 and clinical phenotypes in men.

**Objective:** Our objective was to compare immunoassay and MS measurements of E2 levels in men and evaluate associations with clinical phenotypes.

**Design and Setting:** Middle-aged and older male subjects participating in the population-based Osteoporotic Fractures in Men (MrOS) Sweden study (n = 2599), MrOS US (n = 688), and the European Male Aging Study (n = 2908) were included.

**Main Outcome Measures:** Immunoassay and MS measurements of serum E2 were compared and related to bone mineral density (BMD; measured by dual energy x-ray absorptiometry) and ankle-brachial index.

**Results:** Within each cohort, serum E2 levels obtained by immunoassay and MS correlated moderately (Spearman rank correlation coefficient $r_s = 0.53–0.76$). Serum C-reactive protein (CRP) levels associated significantly (albeit to a low extent, $r_s = 0.29$) with immunoassay E2 but not with MS E2 levels. Similar associations of immunoassay E2 and MS E2 were seen with lumbar spine and total hip BMD, independent of serum CRP. However, immunoassay E2, but not MS E2, associated inversely with ankle-brachial index, and this correlation was lost after adjustment for CRP.

**Conclusions:** Our findings suggest interference in the immunoassay E2 analyses, possibly by CRP or a CRP-associated factor. Although associations with BMD remain unaffected, this might imply a reevaluation of previous association studies between immunoassay E2 levels and inflammation-related outcomes.

---

Immunoassay-based techniques are routinely used in clinical and research settings for the measurement of serum estradiol (E2) levels. They have, however, a questionable specificity, especially at lower E2 concentrations, making this method unreliable in postmenopausal women and men (1–3). Assays based on mass spectrometry (MS) represent the gold standard method for the quantification of E2 in serum samples (4).

---

* C.O. and M.E.N. contributed equally to this work.
† Author affiliations are shown at the bottom of the next page.
Abbreviations: ABI, ankle-brachial index; BMD, bone mineral density; CRP, C-reactive protein; CVD, cardiovascular disease; E2, estradiol; EMAS, European Male Aging Study; MrOS, Osteoporotic Fractures in Men Study; MS, mass spectrometry.
E2 has a pivotal role for bone mineral density (BMD) in men, with both cross-sectional and prospective studies describing associations between serum E2, mostly measured by immunoassay-based techniques, and musculoskeletal outcomes (for review see Reference 5). However, the lack of precise MS-based E2 assays may have contributed to the conflicting results regarding the association between E2 and other, nonmusculoskeletal clinical outcomes in men, eg, mortality and cardiovascular disease (CVD) (6–11).

The aim of the present study was to compare serum E2 levels assessed by both immunoassay-based techniques and MS technology in a large number of middle-aged and older men. We hypothesized that measurement of E2 concentrations by MS will be the more informative and reliable method and therefore should be used when investigating putative associations between serum E2 and clinical variables in men.

Materials and Methods

Study sample

The correlations between immunoassay and MS measurements of serum E2 were evaluated in the Osteoporotic Fractures in Men (MrOS) Sweden (n = 2599), MrOS US (n = 688), and European Male Aging Study (EMAS; n = 2908) cohorts. Details of the study sample are given in the Supplemental Material and Supplemental Tables 1–3 (published on The Endocrine Society’s Journals Online web site at http://jcem.endojournals.org).

Serum analyses and clinical phenotypes

Serum E2 levels were measured by both immunoassay (RIA or electrochemiluminescence) and MS in each study subject for all 3 cohorts. Details are given in the Supplemental Material and Supplemental Tables 4 and 5. Serum levels of high-sensitivity C-reactive protein (CRP) in MrOS Sweden and EMAS were measured by an immunoturbidimetric and a chemiluminescent immunometric assay, respectively, as described in the Supplemental Material.

Areal BMD of the lumbar spine and the proximal femur was assessed using dual-energy X-ray absorptiometry in MrOS Sweden and EMAS. Ankle-brachial index (ABI) in MrOS Sweden was calculated for each leg by dividing the posterior tibial systolic pressure by the upper extremity pressure, and the lowest ABI was used. Details of these measurements are given in the Supplemental Material.

The assessment of the covariates in each cohort and of the parameters used for screening in MrOS Sweden is also described in the Supplemental Material.

Statistical analyses

Agreement of serum E2 assay techniques was evaluated by calculating Spearman rank correlation coefficients and visualized using Kernel density plots and Bland-Altman analyses. Associations among the study variables were examined with Spearman rank correlations. The independent associations between serum E2 levels, measured either by immunoassay or MS, and clinical phenotypes (lumbar spine and total hip BMD and ABI) were calculated using multiple linear regression models. Differences in the mean serum E2 levels, measured either by immunoassay or MS, according to quintiles of CRP were assessed using ANOVA followed by a Tukey’s post hoc test. Values are given as means ± SD, unless otherwise indicated.

Results

Characteristics of the study subjects and assays

The baseline characteristics of the study subjects in the MrOS Sweden, MrOS US, and EMAS cohorts are shown in Supplemental Tables 1–3. The subjects from the MrOS Sweden and MrOS US cohorts are older men, whereas the participants in EMAS are middle-aged men. The characteristics of the immunoassays and MS techniques used to analyze serum E2 are presented in Supplemental Tables 4 and 5.

Assessment of agreement and bias between methods for the analysis of serum E2 in men

The MS techniques were cross-calibrated using 50 samples from the MrOS US study and displayed a strong correlation (Spearman rank correlation coefficient rs = 0.95, P < .001) (Supplemental Figure 1) (12). However, caution must be taken when interpreting or comparing this concordance level for the 2 MS methods because it was ob-
tained from a small number of selected samples. For more
details, see the Supplemental Material.

When comparing the immunoassay and MS measure-
ments of serum E2 in each of the 3 cohorts, rS was 0.53 in
MrOS US (P < .001), 0.64 in MrOS Sweden (P < .001),
and 0.76 in EMAS (P < .001) (3), demonstrating a rather
moderate correlation (Figure 1A and Supplemental Figure
2). The distribution of the immunoassay and MS E2 con-
centrations in the Kernel density plots is shown in Sup-
plemental Figure 3. The Bland-Altman plots showed that
in the MrOS Sweden cohort, immunoassay E2 levels were
on average slightly higher than those obtained with MS
(Supplemental Figure 4A), whereas in the MrOS US co-
hort, immunoassay E2 levels were somewhat lower than
those obtained by MS (Supplemental Figure 4B).

**Serum CRP levels associate with serum E2 levels
measured by immunoassay**

To investigate whether standard population character-
istics associated differentially with both E2 assay tech-
niques used, the MrOS Sweden cohort was used as a
screening cohort to evaluate the associations between se-
rum E2 levels obtained by either immunoassay or MS and
general characteristics, metabolic parameters, CRP, and
lifestyle factors (Supplemental Table 6). Importantly, spe-
cifically for serum CRP levels, the association differed sub-
stantially according to the E2 measurement technique:
CRP levels associated significantly (albeit to a low extent)
with immunoassay-based E2 levels (rS = 0.29, P < .001)
but not with the E2 values measured by MS (rS = −0.01,
P = NS) in MrOS Sweden (Supplemental Table 6). The
fasting state did not affect this association (fasting serum
samples, n = 1797, rS = 0.29, P < .001 for the immuno-
assay method; rS = −0.02, P = NS for the MS method).
A similar association between serum CRP levels and E2
levels, measured by immunoassay (rS = 0.11, P < .001)
but not by MS (rS = 0.03, P = NS) was also observed in
the EMAS cohort. Analyzing serum E2, measured either
by immunoassay or MS, according to quintiles of CRP,
illustrated that with each quintile increment in serum
CRP, there is also an increase in mean immunoassay E2
levels but not mean MS E2 values (Figure 1B).

**Associations of immunoassay- and MS-based E2
levels with clinical phenotypes**

Similar associations of immunoassay E2 and MS E2
were seen with lumbar spine and total hip BMD in both the
MrOS Sweden and EMAS cohorts, independent of serum
CRP levels (Table 1). As expected, ABI, which is lowered
in atherosclerosis-based lower-extremity peripheral arte-
rial disease (13), was negatively associated with serum
CRP levels in the MrOS Sweden cohort. Importantly, se-
rum E2 measured by immunoassay, but not by MS, was
significantly inversely associated with ABI (Table 1). This
association between immunoassay E2 and ABI was lost
after adjustment for CRP levels.

**Discussion**

The 2 MS methods used to measure serum E2 levels in this
study revealed a strong correlation, as was shown previ-
EMAS. The ABI analyses included 2471 subjects from MrOS Sweden.

Also, previous findings of associations between high serum E2 levels and ABI in the present study may be misleading. Observed inverse relation between serum immunoassay E2 levels associated inversely with ABI. Importantly, this association was lost after adjustment for serum CRP, suggesting interference with the E2 immunoassay, possibly by CRP or a CRP-associated factor. Previous studies investigating the relation between serum CRP and E2 levels in men provided conflicting results, probably because of different assay methods used (14–17).

We then assessed the impact of this interference on the putative associations between serum E2 levels and clinical phenotypes. Peripheral arterial disease has been reported as atherosclerotic CVD (7, 8, 10) may have been the result of interference with the immunoassay-based E2 levels. Indeed, similar to the lack of association between MS-based E2 levels and ABI in the present study, we found no association between MS-based E2 levels and cardiovascular events in the Swedish MrOS study (11). Therefore, it seems appropriate to suggest a reevaluation of previous association studies between immunoassay-based E2 levels and CVD phenotypes or other inflammation-related end points in studies with MS E2 levels available. In this respect, a recent study by Yeap et al (18) reported a lack of association of low E2 levels measured by liquid chromatography tandem MS and CVD, diabetes, and frailty.

As an alternative sex steroid-dependent phenotype, the relation between serum E2 and BMD was evaluated. We found similar associations between immunoassay E2 or MS E2 and lumbar spine and total hip BMD, regardless of CRP levels. Moreover, Khosla et al (19) confirmed that serum E2 levels analyzed by MS showed a similar correlation with BMD parameters, as previously found for levels measured by a validated high-sensitive RIA. This suggests that there is no detected interference in the relation between serum E2 levels measured by immunoassay and clinical phenotypes when the investigated phenotype is BMD.

Table 1. Independent Associations Between Serum E2 Levels Measured Either by Immunoassay or MS and Sex Steroid-Related Phenotypes

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Immunoassay E2</th>
<th>MS E2</th>
<th>hsCRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine BMD, g/cm² per quintile</td>
<td>0.016 ± 0.003 (&lt;0.001)</td>
<td>0.019 ± 0.003 (&lt;0.001)</td>
<td>0.001 ± 0.003 (NS)</td>
</tr>
<tr>
<td>MrOS Sweden</td>
<td>0.014 ± 0.004 (&lt;0.01)</td>
<td>0.012 ± 0.005 (&lt;0.05)</td>
<td>−0.006 ± 0.005 (NS)</td>
</tr>
<tr>
<td>EMAS</td>
<td>0.010 ± 0.002 (&lt;0.001)</td>
<td>0.013 ± 0.002 (&lt;0.001)</td>
<td>−0.004 ± 0.002 (&lt;0.05)</td>
</tr>
<tr>
<td>Total hip BMD, g/cm² per quintile</td>
<td>0.009 ± 0.003 (&lt;0.05)</td>
<td>0.008 ± 0.004 (&lt;0.05)</td>
<td>−0.005 ± 0.004 (NS)</td>
</tr>
<tr>
<td>MrOS Sweden</td>
<td>−0.007 ± 0.002 (&lt;0.01)</td>
<td>0.004 ± 0.002 (NS)</td>
<td>−0.017 ± 0.002 (&lt;0.001)</td>
</tr>
<tr>
<td>EMAS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: hsCRP, high-sensitivity C-reactive protein. Age, BMI, and study center-adjusted multiple linear regression analyses with lumbar spine BMD, total hip BMD, or ABI as the dependent variable and immunoassay E2, MS E2, or hsCRP (model 1), immunoassay E2 and hsCRP (model 2), or MS E2 and hsCRP (model 3) as independent variables were conducted. Immunoassay E2, MS E2, and hsCRP were included as quintiles in the models. SE and β-values are given, with P values in parentheses. The BMD analyses included 2560 subjects from MrOS Sweden and 750 from EMAS. The ABI analyses included 2471 subjects from MrOS Sweden.
possible that both the E2 and CRP immunoassays were affected by a separate or common interfering or cross-reacting substance or by matrix effects, unrelated to CRP or inflammation. We are, to the best of our knowledge, not aware of any previous reports of CRP-related or inflammation-related interference of immunoassays for other analytes.

This study has several limitations. The results are based on a single measurement of serum E2; therefore, we were unable to test the reproducibility of these measurement techniques. Furthermore, we were not able to compare the more specific indirect, extraction-based immunoassay methods with the MS method. Still we evaluated the direct immunoassays which are most often used clinically and have been the measurement technique of choice in the vast majority of clinical epidemiological studies.

In conclusion, our findings suggest interference in the standard immunoassay-based E2 analyses, possibly by CRP or a CRP-associated factor. Although this interference does not seem to affect association studies between immunoassay E2 levels and skeletal parameters, we propose a reevaluation of previous association studies between immunoassay-based E2 levels and inflammation-related outcomes. In addition, MS-based assays are to be preferred for the quantification of E2 levels in men.

### Acknowledgments

We thank the men who participated in the 8 countries, the research/nursing staff in the 8 centers: C. Pott (Manchester), E. Wouters (Leuven), M. Nilsson (Malmö), M. del Mar Fernandez (Santiago de Compostela), M. Jedrzejowska (Łódź), H.-M. Tabo (Tartu), and A. Heredi (Szeged) for their data collection; C. Moseley (Manchester) for the data entry and project coordination; and M. Machin (Manchester) for preparing the dual energy x-ray absorptiometry data. The EMAS Study Group includes the following: Florence (Gianni Forti, Luisa Petrone, and Giovanni Corona); Leuven (Dirk Vanderschueren, Steven Boonen, and Herman Borghs); Łódź (Krzysztof Kula, Jolanta Slowikowska-Hilczer, and Renata Walczak-Jedrzejowska); London (Ilpo Huhtaniemi); Malmö (Aleksander Giwercman); Manchester (Frederick Wu, Alan Silman, Neil Pendleton, Terence O’Neill, Joseph Finn, Philip Steer, David Lee, and Stephen Pye); Santiago (Felipe Casanueva, Mary Lage, and Ana I Castro); Szeged (Gyorgy Bartfai, Imre Földesi, and Imre Fejes); Tartu (Margus Punab and Paul Korrovitz); and Turku (Min Jiang).

Address all correspondence and requests for reprints to: Claes Ohlsson, MD, PhD, Professor, Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Vita Stråket 11, SE-413 45 Gothenburg, Sweden. E-mail: claes.ohlsson@medic.gu.se.

The MrOS Sweden study is supported by the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg’s Foundation, the Petrus and Augusta Hedlunds Foundation, and the Novo Nordisk Foundation. The MrOS US study is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Center for Research Resources, and the National Institutes of Health Roadmap for Medical Research under the following grants: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. The European Male Aging Study is funded by the Commission of the European Communities Fifth Framework Programme, Quality of Life and Management of Living Resources, Grant QLK6-CT-2001-00258 and supported by Arthritis Research UK. The principal investigator of the European Male Aging Study is Professor Frederick Wu, MD (Department of Endocrinology, Manchester Royal Infirmary, Manchester, UK). K.A.W. is a senior research scientist working within the Nutrition and Bone Health Core Program at the Medical Research Council Human Nutrition Research, funded by the UK Medical Research Council Grant (U105960371). D.V. is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven (Belgium). S.B. is a senior clinical investigator of the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) and is the holder of the Leuven University Chair in Gerontology and Geriatrics.

Disclosures: The authors have nothing to disclose.
References


Mark Your Calendar for the Reducing Health Disparities Summit, March 22-23, 2013, Sheraton Baltimore Inner Harbor

www.endo-society.org